Sobi™ Satellite Symposium

Agenda

Evolving strategies and challenges in R/R DLBCL - Andrew Davies (UK)

Can preclinical data help? Insights from pharmacology - Romano Danesi (Italy)

Learnings from clinical trials and RWE - Gloria Iacoboni (Spain)

Clinical decision-making in practice - Marek Trněný (Czech Republic)

Treatment sequencing on the horizon: What is next? - Andrew Davies (UK)

Q&A Session and Closing Remarks - All, Andrew Davies (Chair)

Download Slides (2.77 MB)

Publication

18th ICML •
20 June, 2025 •
•

Initial Results From LOTIS-7: A Phase 1b Study of Loncastuximab Tesirine Plus Glofitamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Juan Pablo Alderuccio, Craig Okada, Gilles Crochet, Emily C. Ayers, Marie Hu, Silvia Ferrari, Paolo Caimi, Mehdi Hamadani, Julien Depaus, Enrico Derenzini, Jose Sandoval-Sus, Ruben Reyes, Andrzej Urban, Erica Rave, Adina Graf, Eva Tiecke, Marie Toukam, Pier Luigi Zinzani

Available materials

Oral Presentation

Symposium

EHA •
14 June, 2025 •
•

Dissecting Treatment Sequencing in Relapsed/Refractory Diffuse Large B-cell Lymphoma From Laboratory to Real Life

Pier Luigi Zinzani, Romano Danesi, Joel Wight, Marek Trněný

Available materials

Treatment sequencing in R/R DLBCL: Dissecting the emerging challenge from bench to bedside

Initial Results From LOTIS-7: A Phase 1b Study of Loncastuximab Tesirine Plus Glofitamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Dissecting Treatment Sequencing in Relapsed/Refractory Diffuse Large B-cell Lymphoma From Laboratory to Real Life

Updated Safety Run-In Results From LOTIS-5: A Phase 3, Randomized Trial of Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Patients With R/R DLBCL/HGBL

Initial Results from LOTIS-7: A Phase 1b Study of Loncastuximab Tesirine Plus Glofitamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

QSP Modeling of Loncastuximab Tesirine-lpyl Combined with T Cell–Dependent Bispecific Antibodies Bridges Knowledge and Dose Regimen Strategy

Treatment sequencing in R/R DLBCL: Dissecting the emerging challenge from bench to bedside

Initial Results From LOTIS-7: A Phase 1b Study of Loncastuximab Tesirine Plus Glofitamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Dissecting Treatment Sequencing in Relapsed/Refractory Diffuse Large B-cell Lymphoma​ From Laboratory to Real Life

Updated Safety Run-In Results From LOTIS-5: A Phase 3, Randomized Trial of Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Patients With R/R DLBCL/HGBL

Initial Results from LOTIS-7: A Phase 1b Study of Loncastuximab Tesirine Plus Glofitamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

QSP Modeling of Loncastuximab Tesirine-lpyl Combined with T Cell–Dependent Bispecific Antibodies Bridges Knowledge and Dose Regimen Strategy

Dissecting Treatment Sequencing in Relapsed/Refractory Diffuse Large B-cell Lymphoma From Laboratory to Real Life